Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
$127.86
$0.29(0.21%)
At close: 4:00 PM EST
$127.86
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$84.23 - $160.18
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.18M
Market Cap
$12.83B
Enterprise Value$12.53B
Total Cash (Recent Filing)$1.48B
Total Debt (Recent Filing)$415.30M
Price to Earnings (P/E)29.5
Beta0.67
Next Earnings
May 06, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.48
Shares Outstanding100,363,464
10 Day Avg. Volume954,967
30 Day Avg. Volume1,179,158
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)4.34
Price to Sales (P/S)4.93
P/FCF Ratio18.85
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.38
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda17.43
Forecast
1Y Price Target
$176.55Price Target Upside38.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)5.81
Revenue Forecast (FY)$3.44B
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionSurveys and physician checks indicate broad uptake of Crenessity among academic and community endocrinologists, suggesting sustained demand and room to convert many untreated eligible patients.
Pipeline OptionalityLate-stage programs targeting major depressive disorder and schizophrenia offer additional upside that could materially extend revenue growth beyond current products.
Salesforce ExpansionManagement's plan to expand the commercial salesforce for Ingrezza and Crenessity should raise prescriber engagement and increase prescription frequency, supporting volume growth.
Bears Say
New Patient Starts VariabilitySequential declines in new prescription starts for Crenessity and variability across healthcare providers create uncertainty around current adoption and revenue visibility.
Reduced Geographic FootprintSale of the UK rare disease business removes expected European contribution for Crenessity sales and concentrates revenue risk in the US market.
Rising Operating CostsPlanned increases in research and selling expenses to support pipeline development and launches will raise operating costs and could pressure valuation and earnings.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $160.18 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $12.83B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is May 06, 2026 which is in 41 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 11, 2026. The company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.804 by -$0.324.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.15.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,363,464 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.48 in its last earnings report, missing expectations of $1.804. Following the earnings report the stock price went down -10.434%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$176.55 (38.08% Upside)
$176.55 (38.08% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.51%
12-Months-Change
Fundamentals
Return on Equity
16.67%
Trailing 12-Months
Asset Growth
23.56%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution, robust top-line growth (22% YoY), a very successful first-year launch for CRENESSITY (> $300M and ~10% penetration), solid cash generation (+$700M to $2.5B) and meaningful pipeline momentum (Phase II entry for NBI-'890 and two Phase III neuropsychiatry programs with 2027 readouts). Headwinds include pricing/formulary concessions (≈ -4% pricing impact), higher SG&A/R&D investments to support sales force expansion and late-stage trials, and early-launch variability for CRENESSITY with limited prescriber depth (two-thirds of prescribers have only one treated patient). Overall, positives — strong revenue, cash, differentiated clinical data and a growing pipeline — outweigh the manageable near-term commercial and expense challenges.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$176.55
▲(38.08% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.17% Insiders
27.47% Mutual Funds
24.83% Other Institutional Investors
19.08% Public Companies and Individual Investors